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Surgical Management of 
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Abstract
Bronchiectasis is a chronic clinicopathological disease of the lung characterized 
by chronic cough, sputum production, recurrent pulmonary infection, and persis-
tent bronchial dilatation on computed tomography. For many years, bronchiectasis 
associated with high mortality and morbidity particularly before the advent of 
antibiotics. The medical treatment of bronchiectasis includes antibiotic therapy, 
airway clearance, bronchodilators, and anti-inflammatory agents. Surgery is mainly 
performed for localized disease after failure of the medical treatment, including: 
segmentectomy, lobectomy, and pneumonectomy. This chapter highlights the cur-
rent surgical considerations for treatment of bronchiectasis, regarding indications 
of surgery, preoperative evaluation and preparation, available operative procedures, 
postoperative outcomes, and other important surgical issues.
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1. Introduction
Bronchiectasis was originally described by René Laënnec in 1819. This term 
comes from two Greek words; “Bronkhia” and “Ektasis” meaning “Airway widen-
ing”. As a medical term, bronchiectasis refers to chronic lung disease associated 
with irreversible dilatation of the bronchial tree. For many years, it was considered 
as an orphan disease; however, the detection of bronchiectasis has been increased 
in the recent years as a result of increased health awareness and modern advances in 
the imaging techniques [1, 2].
The prevalence of bronchiectasis varies in relation to geographic location. The 
estimated prevalence of bronchiectasis in developed countries (USA, UK, Germany, 
Spain) is up to 566 cases per 100,000, with 40% increase in the past decade [3, 4].  
The recent findings from the British lung foundation’s project showed that around 
212,000 people are currently living with bronchiectasis in the UK, with pre-
dominence of female gender and over-70 age [5]. In USA, 252,362 patients were 
indentified with an average annual prevalence of 701 per 100,000 persons between 
2006 and 2014, with mean age of 76 years, predominace of female gender (65%), 
and dual diagnosis of chronic obstructive pulmonary disease (COPD) in most of 
the patients (51%) [6]. In China, the overall prevalence of physician-diagnosed 
bronchiectasis in people aged 40 years or older is estimated at 1.2% and is trending 
upward with aging of the population [7]. In comparison to European estimates, the 
recently reported patients with bronchiectasis in India were younger (median age 
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of 56 years), more likely to be men, and showed a high frequency of severe, cystic 
bronchiectasis. Tuberculosis and other severe infections were the most frequently 
reported underlying cause [8].
Most of the cases of bronchiectasis are idiopathic in etiology, however, it may be 
found in a variety of pulmonary diseases, genetic or acquired, such as cystic fibrosis 
(CF), Kartagener syndrome (triad of situs inversus, chronic sinusitis, and bron-
chiectasis), COPD, alpha 1-antitrypsin deficiency, bronchial asthma, or primary 
immunodeficiencies [9, 10]. In the absence of CF, particularly with post-infectious 
and allergic hypersensitivity causes, the disease is known as non-cystic fibrosis 
bronchiectasis (NCFB) [10].
The pathogenesis of bronchiectasis is based on the “vicious cycle hypothesis” 
which begins by infectious or noninfectious insult to the lung, resulting in neu-
trophil inflammation (proteases) and impairment of the mucociliary clearance 
followed by microbial colonization or infection, bronchial obstruction, and exag-
gerated inflammatory response. The “vicious cycle” (Figure 1) refers to the occur-
rence of repeated infections with repeated impairment of the mucociliary apparatus 
subsequent to infection and inflammation [10–12].
The clinical diagnosis of bronchiectasis is challenging as it manifests early 
non-specific symptoms and signs. However, the presence of chronic cough with 
overproduction of sputum which may worse at the morning increases the index of 
suspicion for bronchiectasis especially in non-smokers [13, 14]. Other significant 
signs of bronchiectasis include: hemoptysis, chronic respiratory failure, pulmonary 
hypertension, and right-sided heart failure [13].
Bronchiectasis can be classified anatomically (cylindrical, varicoid, or cystic), 
and radiologically (localized or diffuse) [14]. Chest radiographs show non-specific 
findings of bronchiectasis such as: atelectatic changes, and hyperinflation [13, 14]. 
High-resolution computed tomography (HRCT) of the chest is a useful imaging 
tool for diagnosis of bronchiectasis and detection of the underlying causes. On 
HRCT, bronchiectatic changes include dilated airways, thick-walled bronchi with 
failed tapering at the periphery of the lung,, ring opacity, tram-track sign, and 
finger-in-glove sign, and signet-ring sign when the dilated bronchi is larger than the 
companion pulmonary artery branch (Bronchial-to-arterial ratio > 1) [14].
Figure 1. 
Vicious cycle of bronchiectasis.
3Surgical Management of Bronchiectasis
DOI: http://dx.doi.org/10.5772/intechopen.93103
A bundle of minimum etiological tests has been recommended by European 
Respiratory Society (ERS) for newly diagnosed patients with bronchiectasis includ-
ing: differential blood count, immunoglobulins (IgA, IgM and IgG), and allergic 
bronchopulmonary aspergillosis (ABPA)-specific tests (total IgE, specific IgE to 
Aspergillus, IgG to Aspergillus and eosinophil count), in addition to sputum culture 
for monitoring of bacterial and non-tuberculous infections [15].
Etiology-specific investigations include: Sweat chloride assessment and cystic 
fibrosis transmembrane conductance regulator (CFTR) genetic analysis for cystic 
fibrosis, serum alpha1-antitrypsin level and phenotyping for Alpha-1-antitrypsin 
deficiency, measurement of nasal nitric oxide levels and ciliated epithelial biopsy for 
primary ciliary dyskinesia, Rheumatoid factor and anti-cyclic citrullinated peptide 
(CCP) for autoimmune/connective tissue diseases, and specific CT findings of con-
genital malformations including Williams-Campbell syndrome (bronchomalacia); 
Mounier-Kuhn syndrome (tracheobronchomegaly) and lung sequestration [16].
Bronchoscopy is not a routine diagnostic tool for bronchiectasis in the era of 
HRCT, but there are several indications for diagnostic bronchoscopy in such cases 
including: exclusion of foreign body obstruction especially in children, exclusion 
of proximal obstruction in adults with localized disease, obtaining microbiological 
results in acute ill patients, sampling of lower respiratory tract secretions when serial 
sputum testing did not yield results, obtaining endobronchial biopsy of airway cilia, 
and localizing the site of bleeding in patients with bronchiectasis and hemoptysis [17].
The age-adjusted mortality rate for both male and female patients with diag-
nosed bronchiectasis is more than twice the mortality in the general population 
[4]. The independent risk factors influencing long-term mortality (over 13 years) 
in patients with bronchiectasis include: age, St George’s Respiratory Questionnaire 
activity score, Pseudomonas aeruginosa infection, total lung capacity (TLC), residual 
volume/TLC, and the transfer factor coefficient [18]. Therefore, in order to reduce 
the suspected poor prognosis with bronchiectasis, the treatment should be directed 
to improve symptoms, enhance quality of life, reduce exacerbations, and limit 
progression of the bronchiectatic lesions [15, 19].
Treatment of bronchiectasis has been considered by ERS guidelines according to 
the vicious cycle hypothesis [15]. Thus, the options of treatment include: long-term 
inhaled or oral antibiotic therapy, eradication of new pathogenic microorgan-
isms and antibiotic treatment of exacerbations for chronic bronchial infection, 
long-term anti-inflammatory therapies for inflammation, long-term mucoactive 
treatments and airway clearance techniques for impaired mucociliary clearance, 
and long-term bronchodilator therapy, surgery and pulmonary rehabilitation for 
structural lung disease.
2. Indications of surgery
Optimization of the medical management and proper selection of patients are 
crucial in the decesion making for surgery. Therefore, the current guidelines by ERS 
and British Thoracic Society (BTS) did not consider surgery until the symptoms 
are controlled by optimized medical treatment [15, 20]. The indications of surgery 
as recently mentioned by BTS guideline (Figure 2) include: persistent symptoms 
despite up to a year of comprehensive medical treatment, exacerbations that are 
either severe or frequent and interfere with social/professional life, recurrent 
refractory or massive hemoptysis, post obstruction bronchiectasis distal to tumors, 
localized severely damaged lobe/segment that may be a source of sepsis that left in 
situ may lead to extension of lung damage, and treatment of complications such as 
empyema or lung abscess [20].
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Up to date, there are only 46 published studies in literature between 1960 and 
2019, evaluating the surgical management of bronchiectasis [21–66]. The most 
common clinical manifestations in these studies were: productive cough in 17.4–
100% [54, 57], fetid sputum in 15.1–80% [35, 57], and hemoptysis in 10–76.5% [44, 
59], while the main and indications of surgery include: failure of medical therapy 
in 39.6–100% [43, 50], recurrent chest infection in 19.8–100% [23, 54], massive or 
recurrent hemoptysis in 3–44.3% [32, 43], lung abscess in 1.8–36.5% [32, 58], lung 
masses or tumors in 1.4–17.6% [42, 46], and empyema in 1.1–8.1% [30, 57]. The 
mean duration of symptoms before surgery ranged from 1.78–10.6 years [30, 66].
Failure of prudent medical treatment is the main indication of surgery in these 
studies, especially with frequent exacerbations and repeated hospitalizations [41]. 
Some authors considered failure of treatment if sputum production persists after 
2 or 3 cycles of treatment [35]. The permanently damaged areas of bronchiectasis 
have poor antibiotic penetration leading to failure of antibiotic therapy, and acts as 
a microbiological reservoir with subsequent recurrence of infection [61]. Moreover, 
medical treatment for long periods with persistent symptoms has additional 
psychological and social effects [32].
Therefore, surgery after failed medical treatment should aim to improve clini-
cal condition and health-related quality of life, in addition to resolution of terrible 
bronchiectasis-related complications. This aim can be achieved when the focal 
lesions are completely removed, however, patients with multisegmental lesions 
should have palliative limited resection after failure of medical treatment or in the 
presence of life-threatening hemoptysis [47].
Recurrence of pulmonary infection is an important indication of surgery, as it 
can result in increased cost and side effects of antibiotic therapy for acute infection, 
in addition to affection of the normal lung tissue with extension of lung destruction 
during each episode [32]. When bronchiectasis is associated with lung abscess, sur-
gery should be delayed until adequate control with antibiotic therapy and avoiding 
Figure 2. 
Current indications for surgical treatment of bronchiectasis [15, 20].
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of preoperative drainage is recommended, however, the immediate indications of 
surgery in the presence of lung abscess include increased abscess size, unceasing 
sepsis, and contralateral contamination [30].
Recurrent or massive hemoptysis of more than 600 mL of blood within 24 hours 
indicates surgery which is considered as emergency after failure of the conservative 
therapy for hemoptysis. Even after initial cessation of bleeding by balloon blockade 
of the bleeding bronchus or bronchial artery embolization, early surgical treatment 
is indicated to avoid life-threatening recurrence of hemoptysis [30].
In children, the indications for surgery are the same as in adult patients. Growth 
retardation can be considered as an additional indication for surgery in children 
with satisfactory postoperative results [43]. It is crucial to exclude the underlying 
diseases such as Kartagener syndrome and cystic fibrosis which limit the surgical 
resection [36].
3. Preoperative evaluation
Preoperative evaluation should include physical examination, imaging stud-
ies, arterial blood gases, pulmonary function tests, bronchoscopy, and perfusion 
scans if indicated. Additional diagnostic work-up may be required for patients with 
cardiovascular diseases including echocardiography, stress testing, myocardial 
perfusion studies, and coronary angiography [48].
3.1 Chest radiography
Chest radiography represents non-specific features of bronchiectasis with 
low sensitivity and difficult appreciation. The suggestive findings in moderate to 
severe patients include: stranding, cystic lesions, volume loss with crowding of 
vessels, atelectasis, tram-track appearance, ring-like opacities, and tubular densities 
[28, 67]. Despite inadequate role of chest radiography in evaluation of bronchiec-
tasis, abnormalities on chest radiography is significantly correlated with severity of 
the disease on HRCT [68].
3.2 High resolution computed tomography (HRCT)
The images of HRCT have higher sensitivity for diagnosis and localization of 
bronchiectasis than radiography with very low false negative and false positive 
results [41, 69]. The indications of HRCT include: clinical suspicion despite 
normal chest radiography, clarification of abnormalities on chest radiography, 
and decision making for surgery [70]. The use of HRCT is not restricted by age 
of the patient, thus HRCT is not uncommon diagnostic tool in children with 
bronchiectasis [56].
In addition to the great help of HRCT in diagnosis of different types of bron-
chiectasis (Figure 3), preoperative localization of the lesions by HRCT has specific 
importance in making the decision for complete anatomic resection or limited 
resection with preservation of the lung tissue [30].
3.3 Bronchoscopy
Bronchoscopy should be performed in all patients to determine the underlying 
causes of bronchial obstruction including: foreign body aspiration, endobronchial 
epithelial tumors, and enlarged hilar lymph nodes with lobar collapse [30, 36]. 
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Preoperative removal of the secretions and clearing of the airways is an important 
indication of bronchoscopy in adult and children patients [63], as it is associated 
with lower rate of postoperative complications [41].
3.4 Pulmonary function tests
Pulmonary function tests (PFTs) are not routinely performed in cases of 
bronchiectasis when the lesions are localized, but PFTs should be performed in 
diffuse bronchiectasis and in cases of repeated operations [36]. Pulmonary func-
tion tests can be performed in adult patients or in children older than 6 years of age 
[59]; however, cooperation of the child may affect completeness of the pulmonary 
function tests [35].
The patients with bronchiectasis may have obstructive ventilatory pattern 
related to mucus retention or immunological abnormalities. The surgical resection 
of pulmonary segments with little contribution to ventilatory process is expected to 
have no or minimal effect on postoperative pulmonary function [31]. The expected 
loss of pulmonary function after surgical resection of bronchiectasis can be calcu-
lated from the equation: expected loss of function = preoperative function * (num-
ber of functional segments in the lobe to be resected/total number of segments of 
both lungs) [53].
3.5 Perfusion scans (ventilation/perfusion scintigraphy)
Ventilation/perfusion (V/Q ) scintigraphy provides information about hemody-
namic features (vascular perfusion), gas exchange, and quantitative lung function, 
which has a particular help in cases with diffuse bronchiectasis as it can determine 
the most affected non-perfused areas to be surgically resected [36, 37]. The affected 
area is considered non-perfused when the perfusion is <10% of the expected [37]. 
Moreover, V/Q scintigraphy is indicated in patients with poor pulmonary function 
to provide more quantitative information about ventilation function [38].
Some authors tried to find the correlation between morphologic type of bron-
chiectasis and the hemodynamic perfusion features. The study by Ashour in 1996, 
determined a correlation of cylindric morphology with pulmonary perfusion, 
contrary to non-perfusion predominance in cystic type, thus the surgery for diffuse 
bronchiectasis can be reserved for non-perfused cystic lesions which are more dam-
aged than cylindrical lesions [71]. Thereafter, Al-Kattan and colleagues reported 
a new hemodynamic classification of bronchiectasis in patients with diffuse or 
bilateral disease, combining the perfusion and morphologic features to provide 
a reasonable extent of surgery and to obtain maximum postoperative clinical 
improvement [37].
Figure 3. 
Images of high resolution computed tomography show types of bronchiectasis: (A) cylindrical, (B) varicose, and 
(C) cystic.
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4. Preoperative preparation
The preoperative preparation of patients with bronchiectasis should aim to 
provide the best possible status. Therefore, the preoperative preparation should be 
performed by a multidisciplinary team consists of infectious disease specialists, 
pulmonologists, and thoracic surgeons [72].
4.1 Sputum culture analysis
The patients should have appropriate preoperative preparation until the sputum 
volume reduced to 20-50 mL per day [54, 63], or the antibiotic therapy is modi-
fied according to new culture sensitivity results of the sputum [63]. As the gram-
negative bacterial infection has a significant risk for perioperative complications, 
surgery should be performed after negative proof of Gram-negative bacillus on 
sputum culture analysis [58].
In patients with a history of tuberculosis, surgery should be reserved for patients 
with inactive disease. Some surgeons postponed elective surgery 6 months if the 
sputum culture was positive for acid-fast bacilli and after the completion of antitu-
berculosis treatment [41].
4.2 Infection control
Preoperatively, patients should be hospitalized and prepared for at least 2 
weeks before surgery [48]. The patients who are scheduled for surgery should have 
no active pulmonary infection at the time of surgery. Therefore, broadspectrum 
antibiotics should be given for 48 hours prior to surgery, or prophylactic antibiotics 
are given according to results of sputum culture and sensitivity tests [36, 54]. For 
prophylaxis, cephalosporin and aminoglycoside are preferred if the culture is nega-
tive and the patient has no contraindications or allergies [48].
4.3 Chest physiotherapy and postural drainage
The patients should have intensive chest physiotherapy in the preoperative 
period, to obtain acceptable decrease of the daily volume of the sputum [54]. 
Patients should have chest physiotherapy including postural drainage for at least 
2 weeks bfore surgery [57], or it should be continued until the daily sputum is 
≤50 mL [50]. Preoperative postural drainage is essential to clean intra-tracheal 
secretions, decrease the sputum volume and sputum accumulation, and hence 
control of the infection and optimize the respiratory status [50, 58].
The recommended airway clearance techniques are active breathing techniques 
or oscillating positive expiratory pressure (PEP). Review of HRCT findings is 
helpful to determine the appropriate postural drainage in relevance to the affected 
pulmonary segments. The gravity assisted positioning, where not contraindicated, 
is recommended to enhance the effectiveness of an airway clearance technique. 
Modified postural drainage without head down tilt should be considered when 
the postural drainage is not tolerated and when the symptoms of gastroesophageal 
reflux increased with the technique [17, 20].
4.4 Other considerations
Nutritional support and pulmonary rehabilitation should be considered before 
surgical referral [20]. In patients on long-term steroid therapy, the doses may be 
increased by 5–10 mg/day, but surgery should be postponed in patients with uncon-
trolled respiratory symptoms [72].
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5. Surgical procedures
5.1 Thoracotomy
The anesthetic management during surgery for bronchiectasis should consider: 
(1) cleaning of the bronchus opposite to the side of surgery by aspiration before 
placement of endotracheal tube, and (2) avoiding contralateral contamination by: 
insertion of double-lumen endotracheal tube, use of Fogarty embolectomy catheter 
as a bronchus blocker, or advancing of the endotracheal tube to the main bronchus 
of the opposite side of resection [35, 37, 41, 54, 57].
Posterolateral thoracotomy is the standard approach for pulmonary resection 
in patients with bronchiectasis. Preservation of the integrity of chest wall muscles 
using muscle-sparing technique is essential to reduce postoperative pain and gener-
ate an effective cough [29]. When the decision is for bilateral lung resection, the 
second operation can be performed with an interval of 1–4 months [49, 53].
The extent of lung resection is determined by extent of the disease and cardio-
pulmonary reserve, thus lobectomy is performed for lesions limited to one lobe, 
segmentectomy is performed for fairly limited disease or when the pulmonary 
function is impaired, while pneumonectomy is reserved for extensive disease affect-
ing the whole lung [33, 50, 54]. In some instances, bilobectomy and lobectomy plus 
segmentectomy can be performed [40, 44, 48, 50, 52, 61]. Extrapleural dissection is 
preferred to avoid spillage of lung content into pleural space. After identification of 
the hilar structures and opening of the major fissure, arterial, venous, and bron-
chial branches are isolated and divided, respectively [39, 63].
Certain recommendations can be followed to prevent or reduce the incidences 
of postoperative air leak and bronchopleural fistula (BPF) after lung resection 
including: preservation of peribronchial tissues and avoidance of extensive lymph 
node dissection near to bronchi to minimize bronchial devascularization, division 
of the bronchus before mobilization of the resected part to avoid contamination of 
the healthy segments, division of the bronchial stump as short as possible which 
sutured by non-absorbable materials or closed with a mechanical stapler then 
buttressed by tissue glue or a flap from pleura, pericardium, pericardial fat pad, 
muscle, or omentum [41, 73].
To reduce the extension of contamination during surgery, extrapleural intraperi-
cardial pneumonectomy is recommended when there is pleural sepsis or complete 
fusion of the pleura. Also, the evidence of pleural infection indicates pleural space 
irrigation with antibiotic [73]. Following placement of the chest drains, bron-
choscopic evaluation of the bronchial sutures with removal of any secretions in 
the airway should be performed [63]. The resected specimens should be sent for 
histopathological examination [41].
5.2 Video-assisted thoracoscopic surgery (VATS)
There is a little research work regarding use of VATS in the management of bron-
chiectasis. The reported VATS approaches for lobectomy in patients with bronchi-
ectasis include three ports, two ports, or one port VATS [55, 62, 66]. Additionally, a 
two-port thoracoscopy with a utility mini-thoracotomy has been reported [45].
For three ports completely VATS procedure, the ports are placed through the 7th 
or 8th intercostal space in the midaxillary line for a 10-mm 30° thoracoscope, the 
4th or 5th intercostal space along the anterior axillary line (4–5 cm incision), and 
the 7th or 8th intercostal space in the auscultatory triangle (1.5 cm incision) [55]. 
For two ports VATS lobectomy, a 2 cm camera port through the 7th or 8th intercos-
tal space in the anterior axillary line and a 3–5 cm utility incision through the 4th 
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or 5th intercostal space in the anterior or mid axillary line [62]. Ocakcioglu et al. 
described uniportal VATS lobectomy through a utility incision of 3–5 cm from the 
5th intercostal space in the anterior position without use of rib retractor. A 10 mm 
30° thoracoscope is placed in the anterior part of the incision, while dissecting and 
holding clamps are placed through the dorsal part [66].
During 3 ports VATS, the incisions change depending on the type of lung resec-
tion, whether it is an upper or lower lobectomy [62]. The presence of intrathoracic 
adhesions is a challenging problem during VATS which can be released by blunt 
or sharp dissection, or it may result in conversion of the VATS procedure to open 
procedure [55, 64]. As in open thoracotomy, the pulmonary artery is firstly identi-
fied and divided before the division of the veins to avoid congestion of the lobe, 
with separate dissection of the major pulmonary veins and the bronchus [64]. The 
dissection of vascular and airway structures is performed by an endoscopic linear 
cutter [55]. At the end of VATS procedure, the thorax is closed after retrieval of the 
resected specimens and meticulous control of air leak and hemorrhage [66].
5.3 Postoperative care
Bronchoscopy can be performed in the operating room for bronchial hygiene, 
immediately after surgery [56]. The early postoperative care should include: pain 
control including epidural analgesia, chest physiotherapy, antibiotic therapy 
according to results of culture and sensitivity [37, 56].
Generally, the duration of postoperative systematic antibiotic therapy is 5 days, 
but it can be longer according to the inflammatory condition. Early ambulation and 
active cough, and 3–4 times percussive chest physiotherapy are essential for proper 
expectoration and lung re-expansion. The standard criteria for removal of chest 
tube are: stable vital signs, small amount of drainage (<100 mL/day) with clear 
color, lung re-expansion on chest X-ray, and absence of air leak [63].
After discharge, patients should have specific or wide-spectrum antibiotic 
therapy for 1 week. Chest physiotherapy can be reinitiated at home and continued 
for 2 weeks after discharge [33].
6. Postoperative outcomes of lung resection
6.1 Mortality
To date, few studies have evaluated postoperative outcomes after lung resection 
for bronchiectasis (Table 1). There is no perioperative mortality (early, operative, 
in-hospital, postoperative, or 30-days) after surgical resection of bronchiectasis in 
most of the published studies. The reported rates of perioperative mortality ranged 
from 0.41% [23] to 8.3% [25]. The causes of early mortality in literature include: 
respiratory failure [2, 27, 28, 41, 49, 57], intraoperative bleeding [24, 28, 46], post-
operative pneumonia [25, 37], empyema [25, 32], pulmonary edema [27, 46], cardiac-
related causes including myocardial infarction or arrhythmia [27, 35, 47, 49, 58], 
speptic shock [27, 56], gastrointestinal bleeding due to sepsis and stress ulcer [39], 
uncontrolled hemoptysis [27], pulmonary embolism [22, 32, 48, 58], cardiac arrest 
in patients with Kartagener syndrome [36], disseminated intravascular coagula-
tion [44], nephropathy [22], downstream consequences of bronchial stump 
fistula [48, 60], multiple organ failure [48, 60], and causes unrelated to disease or 
technique such as cerebral edema in a child due to previously undiagnosed aquae-
ductus stenosis and hydrocephalus [24]. The disease-related consequences which 
indirectly attribute to early death include: severe disease requiring pneumonectomy 
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Author Year Number Morbidity 
(%)
Early 
mortality (%)
Late  
mortality (%)
Asymptomatic 
(%)
Hewlett and 
Ziperman
1960 107 20.6 0 1.9 36.4
Streete and 
Salyer
1960 240 22.1 0.8 2.1 22.3
Sanderson et al. 1974 242 33.5 0.4 2.9 62.5
George et al. 1979 99 88.9 3 4 39.6
Annest et al. 1982 24 12.5 8.3 8.3 45.8
Wilson and 
Decker
1982 84 10.7 0 1.2 73.8
Dogan et al. 1989 487 10.7 3.1 0.4 73.3
Agasthian et al. 1996 134 24.6 2.2 0 59.2
Ashour et al. 1999 85 12.9 0 0 74.1
Fujimoto et al. 2001 90 22.2 0 0 45.6
Prieto et al. 2001 119 12.6 0 0 67.6
Kutlay et al. 2002 166 10.8 1.8 0 75
Balkanli et al. 2003 238 8.8 0 0 82.5
Mazieres et al. 2003 16 18.8 0 0 31.3
Haciibrahimoglu 
et a
2004 35 17.1 2.9 0 64.7
Otgun et al. 2004 54 7.4 5.6 0 45.1
Al-Kattan et al. 2005 66 18.2 1.5 0 73.8
Schneiter et al. 2005 48 18.8 0 0 62.5
Aghajanzadeh 
et al.
2006 29 37.9 3.4 0 67.9
Yuncu et al. 2006 81 18.5 0 0 81.7
Eren et al. 2007 143 23.1 1.4 0 75.9
Guerra et al. 2007 51 15.7 0 0 77.8
Sirmali et al 2007 176 13.1 0 0 73.3
Stephen et al. 2007 149 14.8 0.7 0.7 54.3
Giovannetti 
et al.
2008 45 11.1 0 0 71.1
Bagheri et al. 2010 277 15.9 0.7 0 68.6
Gursoy et al. 2010 92 16.3 1.1 0 84
Zhang et al. 2010 790 16.2 1.1 0 67.7
Caylak et al. 2011 339 12.7 0.6 0 71
Cobanoglu et al. 2011 62 19.4 0 0 45
Gorur et al. 2011 122 13.1 0 0 77.3
Sehitogullari 
et al.
2011 129 22.5 0 0.8 60.2
Hiramatsu et al. 2012 31 19.4 0 0 74.2
Al-Refaie et al. 2013 138 13 0 0 84.2
Zhou et al. 2013 56 23.2 0 0 58.9
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or completion [28, 58], massive bleeding during the operation because of dense 
adhesions due to chronic and recurrent infections [44, 46], and Kartagener syn-
drome [36].
The rates of late or long-term mortality ranged from 0.41% [27] to 8.3% [25]. 
The reported causes of late mortality after surgical management of bronchiectasis 
included: respiratory failure [24, 52], progressive respiratory disease [25], sepsis 
[59], coronary artery thrombosis [22], cor pulmonale or pulmonary heart disease 
[22, 58], myocardial failure [22], glomerulonephritis [22], kidney failure [58], post-
pneumonectomy pneumonia in the remaining lung [56], massive bleeding from the 
Malecot catheter used for drainage ofresidual space infection [44], suicide [22], and 
other causes of late deaths not attributable to bronchiectasis [21, 23, 26].
6.2 Morbidity
The reported rates of morbidity ranged from 7% [7] to 38% [39]. The most 
common complication is atelectasis or sputum retention requiring bronchoscopic 
intervention, followed by persistent air leak (Table 2). Most of the reported com-
plications were minor, transient, and treatable.
In comparison to the published studies in the 3rd and 4th decades of 20th 
century, the relatively low incidences of complication in the after while studies 
can reflect effective antibiotic therapy, improved anesthetic techniques, adequate 
blood transfusion, and detailed postoperative care [21, 22]. Other factors include: 
surgeon’s experience, preoperative awareness of the undesirable consequences 
of retained secretions, preoperative teaching of breathing exercises, scheduling 
tracheal suction or bronchoscopy in the early postoperative period [21], good intra-
operative hemostasis and careful dissection [37], low number of pneumonectomies, 
accurate patient selection, and careful perioperative management [45].
Treatment of postoperative complications after surgery for bronchiectasis depends 
on its type and severity. The treatment options for complications include: physio-
therapy, tube thoracotomy, bronchoscopic treatment for atelectasis, negative suction 
applied to the chest tubes for prolonged air leak, surgical reintervention for closure 
Author Year Number Morbidity 
(%)
Early 
mortality (%)
Late  
mortality (%)
Asymptomatic 
(%)
Andrade et al. 2014 109 36.7 0.9 0.9 NR
Balci et al. 2014 86 16.3 1.2 0 82.6
Jin et al. 2014 260 11.5 0.8 1.9 78
Sahin et al. 2014 60 20 0 3.3 74.1
Vallilo et al. 2014 53 24.5 3.8 0 34.1
Coutinho et al. 2016 69 14.5 0 0 73.3
Baysungur et al. 2017 41 9.8 0 0 NR
Dai et al. 2017 37 21.6 0 0 62.2
Hao et al. 2019 99 17.2 0 0 26
Nega et al. 2019 22 22.7 4.5 0 89.5
Ocakcioglu et al. 2019 14 14.3 0 0 85.7
NR: Not reported.
Table 1. 
Reported outcomes (%) after surgical treatment of bronchiectasis [21–66].
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of bronchopleural fistula, medical treatment or decortication for pleural empyema, 
pharmacological control of supraventricular arrhythmias, reexploration for postop-
erative bleeding, and mechanical ventilation for respiratory insufficiency [39, 41, 60].
Cobanoglu et al. did not report any significant statistical difference between 
tubular and saccular morphologic types of bronchiectasis regarding postoperative 
complication rates; however, the most severe postoperative complication, broncho-
pleural fistula, developed in 2 (3.22%) cases with saccular bronchiectasis [50]. Zhou 
et al. did not find statistically significant difference in the rates of postoperative 
complications between thoracotomy and VATS procedure. Minor postoperative 
complications were reported after thoracotomy or completely VATS lobectomy, 
which included pneumonia, prolonged air leak (>7 days), and atelectasis [55]. 
Moreover, Hao et al. did not observe major postoperative complications such as 
bronchopleural fistula or respiratory insufficiency was observed in VATS and thora-
cotomy groups. The most common complication was persistent air leak for >7 days 
in 8.1% of VATS group and 6% of thoracotomy group [64].
6.3 Symptomatic improvement
The clinical results after surgical resection of bronchiectasis are frequently clas-
sified into three categories. The first category (asymptomatic; excellent response) 
includes patients who are completely free of any symptoms suggestive of bronchiec-
tasis, and considered themselves cured. The second category (clinical improvement; 
good response) includes those considered improved who have had some relief of 
the symptoms but still had some chronic pulmonary complaints. The third category 
(no improvement; poor response) includes patients with no-change, no-reduction 
in preoperative symptoms, or who are worse off since surgical resection. [22, 31, 32, 
35, 44, 46, 47, 50]. Some authors referred to the excellent response as well outcome 
[36] or perfect response [41].
Sanderson et al. expanded the classification of the clinical symptomatic outcome 
to five categories as: excellent (no symptoms at all), good (full physical capacity, 
occasional cough and sputum), fair-improved (tendency to cough and sputum 
Complications Minimum rate 
[Reference]
Maximum rate [Reference]
Atelectasis or sputum retention 0.9% [21] 33.3% [24]
Prolonged air leak 0.7% [54] 26.4% [23]
Pneumonia 1.2% [57] 12.5% [34]
Bronchopleural fistula 0.4% [48] 9.1% [65]
Residual air space or expansion defect 2.2% [45] 9% [51]
Empyema 0.6% [32] 8.1% [44]
Wound infection 1.3% [44] 7.4% [27]
Bleeding 1.1% [30] 8.3% [25]
Cardiac arrhythmias 0.4% [58] 5.4% [63]
Pulmonary embolism 0.4% [58] 3.8% [60]
Respiratory insufficiency 0.8% [52] 3.5% [57]
Pulmonary edema 0.8% [52] 2.2% [28]
Pleural effusion 0.6% [32] 0.7% [54]
Table 2. 
Reported rates of complications after surgical treatment of bronchiectasis.
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with susceptibility to respiratory infection, hemoptysis or dyspnea), poor (residual 
symptoms), and worse (steady deterioration) [23]. Other authors reduced the 
classification of the clinical condition in two categories only by dividing the patients 
into an improved group (“excellent” or “good” outcomes) and an unimproved group 
(“no change” or “worse” outcomes) [52].
In literature, through a range of follow-up between 9 months and 14 years, 
the proportion of asymptomatic patients or excellent improvement after surgery 
ranged from 22.3% [22] to 89.5% [65], while the proportion of clinical improvement 
with reduction of preoperative symptoms ranged from 9.6% [64] to 80.7% [56], 
and no improvement, worseness or relapse was reported in 1.6% [58] to 42.3% [22].
6.4 Quality of life (QOL)
Patients with bronchiectasis report worse quality of life (QOL) than do persons 
in the general population [74, 75]. Recurrent bronchiectasis exacerbations are 
related to deterioration of lung function, progression of the disease, impairment 
of quality of life, and increased rate of mortality [76]. Postoperative QOL and 
the functional consequences of lung resection (pulmonary function and exercise 
capacity) are poorly addressed.
Vallilo et al. reported a significant improvement of the QOL in patients with 
symptomatic bronchiectasis which was particularly relevant in the functional and 
physical QOL domains. Resection of the lung area which had not contributed to 
ventilatory response during exercise before surgery might enable the patients to 
maintain the exercise performance after lung resection without impairment to the 
response of the ventilatory system during maximal testing [60].
6.5 Complete versus incomplete resection
The proper surgical treatment should aim to complete resection of the bronchi-
ectatic lesions. Thus, intraoperatively detected lesions should be resected as appro-
priate whether determined on preoperative imaging studies or not [32]. Complete 
resection is defined as an anatomic resection of all affected segments preoperatively 
identified by high-resolution computed tomography or bronchography [48, 54, 57]. 
However, some authors considered pulmonary resection complete if the patient was 
believed to be free of bronchiectasis after thoracotomy [31, 35].
Completeness of surgical resection is affected by localization of the disease and 
pulmonary function (Figure 4). In patients with unilateral localized bronchiectasis, 
the most important prognostic factor for good surgical outcomes is complete resec-
tion of all diseased segments. In bilateral localized bronchiectasis, complete surgical 
resection should be attempted if lung function permits, including combinations of 
lobectomy with segmentectomy or wedge resections on the same siting or staged 
[24, 39, 73]; however, limited resection of the most predominant lesion is preferred 
for selected patients with bilateral diffuse bronchiectasis [34, 63]. The reported 
completeness of resection in patients with localized bronchiectasis ranged from 
55.4% [23] to 94.2% [54].
Sanderson et al. found a preponderance of excellent results after complete resec-
tion in comparison with incomplete resection (36% versus 10%, P < 0.005) [23]. 
Agasthian et al. found that complete resection resulted in a significant increase in 
proportion of asymptomatic patients than incomplete resection (65.2% versus 21.4%, 
p < 0.05) [28]. In the study by Kutlay et al., the excellent to good results of complete 
resection were significantly better than those of incomplete resection (98.5 versus 
76.5%, P < 0.05) [32]. Similarly, other authors reported significantly better clinical 
results with complete resection than incomplete resection [35, 36, 44, 46, 50, 52].
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6.6 Predictors of postoperative outcomes
There is no single independent perioperative variable that can predict occur-
rence of adverse events after lung resection with scant available data. In the study 
by Fujimoto et al., the logistic analyses extracted the type of bronchiectasis (cylin-
drical or others), the history of sinusitis, and the type of resection (complete or 
incomplete) for discrimination between patients with excellent or improved clinical 
outcome and patients with no clinical change [30]. Hiramatsu et al. reported 
immuno compromised status, Pseudomonas aeruginosa infection, and extent of 
residual bronchiectasis, as independent and significant factors of postoperative 
shorter relapse-free interval [53].
Eren et al. fond that the lack of preoperative bronchoscopic examination, a 
FEV1 of <60% of the predicted value, a history of tuberculosis, and incomplete 
resection were independent predictors of postoperative complications [41]. Bagheri 
et al. statistically evaluated several variables including: sex, age, localization of 
disease, and complete or incomplete resection using multivariate logistic regres-
sion. Complete resection was found to have a significantly better surgical outcome 
compared to incomplete resection [46]. In the study by Zhang et al., the logistic 
regression analysis showed that tuberculous bronchiectasis, type of bronchiectasis 
(saccular versus others), and type of resection (incomplete or complete) were three 
independent factors associated with poor surgical outcome [48]. The multivari-
able analyses by Jin et al., showed that age, sputum volume, gram-negative bacillus 
infection, and bronchial stump coverage were the four independent factors related 
with poor surgical outcome [58].
According to the reported results by Sahin et al., the prognostic variables in 
pediatric patients were: FEV1 less than 60% of the predicted value, hemoptysis, and 
duration of symptoms [59]. Interestingly, Gorur et al. stated that multi-segmental 
resectable bronchiectasis should not be considered an occult risk factor for morbid-
ity after lung resection. Moreover, the number of resected segments, hemoptysis, 
and absence of preoperative fiberoptic bronchoscopy were not associated with 
postoperative complications. Impaired pulmonary function was significantly 
associated with residual air space; however it did not predict the risk of persistent 
air leak, atelectasis or empyema [51].
Completion pneumonectomy is historically recognized as a high-risk procedure 
especially when done for a benign disease [77]. To reduce the high-risk of comple-
tion pneumonectomy when indicated, precautions such as optimal exposure, 
Figure 4. 
Simplified algorithm for complete surgical resection according to extent of bronchiectasis.
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intrapericardial isolation of blood vessels, and bronchial reinforcement are recom-
mended [78]. In the study by Agasthian et al., all died patients after lung resection 
had completion pneumonectomy. The causes of death were respiratory failure 
and intraoperative bleeding [28]. However, Fujimoto et al. reported acceptable 
mortality and morbidity after completion pneumonectomy without mortality and 
only one patient had postoperative bronchopleural fistula that could be managed 
conservatively [30].
7. Specific surgical considerations
7.1 Non-localized bronchiectasis
Patients with non-localized (multi-segmental or bilateral) bronchiectasis are 
generally regarded as an exclusion of surgery [39]. However, considering the limited 
and palliative effect of medical treatment and the risk of transplantation or radical 
operation, recent studies offered a limited operation to some of these patients [34, 
63]. Moreover, some surgeons favored surgery in non-localized bronchiectasis to 
prevent extension of the disease to the unaffected lung [38].
George et al. suggested that bilateral bronchiectasis need not be a contraindica-
tion to operation. In properly selected patients, lasting symptomatic improvement 
can be provided by resection [24]. Mazieres et al. reported favorable outcome after 
a limited lung resection in properly selected symptomatic patients with severe 
multisegmental bilateral bronchiectasis, particularly those with cystic lesions and 
functionless territories [34].
Schneiter et al. found the same patients’ satisfaction at 6 months after surgery 
for patients who had resectable non-localized or localized bronchiectasis, with 
non-significant differences in the rates of recurrent infection and hemoptysis [38]. 
Aghajanzadeh et al. reported the benefits of surgery in 87 bilateral non-localized 
bronchiectases, and concluded that staged bilateral resection for bronchiecta-
ses can be performed at any age with acceptable morbidity and mortality [39]. 
Additionally, Dai et al. reported the safety of lobectomy for the predominant lesions 
in non-localized bronchiectasis, with significant relief of symptoms, good rates of 
satisfaction, no operative mortality, and minimal postoperative complications [63].
7.2 Surgery for bronchiectasis in children
The prevalence of bronchiectasis in children ranges from 0.2 to 735 cases 
per 100,000 [79]. Cystic fibrosis is the most common cause of bronchiectasis in 
developed countries while in developing countries non-CF etiologies particularly 
post-infectious causes are more common [80]. Surgical treatment of bronchiec-
tasis in children is considered for cases with resectable disease after failure of the 
proper medical treatment. Moreover, surgery can be considered in children with 
diffuse disease who have expected benefit after excision of the most predominant 
lesions [36, 79].
In literature, the studies that evaluate surgical treatment of bronchiectasis in 
children are scanty. However, these studies confirmed the safety of surgery for 
childhood bronchiectasis with low rates of mortality and morbidity. Complete 
resection can be considered when possible, as most of the children can benefit from 
surgery especially if the total excision is accomplished [26, 35, 36, 43, 56, 59].
The reported surgical outcomes in children with bronchiectasis highlight: 
acceptable mortality and morbidity [35, 36, 43, 56, 59], significant impact of 
surgery on improvement of symptoms and quality of life [43, 56], good results 
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after segmentectomy when the pulmonary segment is entirely free of disease [26], 
increase the chance of cure after complete resection which results in significantly 
better outcome than incomplete resection [35, 43], preference of pneumonec-
tomy instead of leaving residual disease when bronchiectasis is unilateral [36], 
and significant impact of duration of symptoms and timely intervention on the 
 management and prognosis [59].
8. Conclusions
Bronchiectasis is a significant chronic lung disease associated with vicious cycle 
of inflammation, infection, mucus accumulation, and structural tissue damage. 
Current guidelines recommend surgical treatment of bronchiectasis in patients with 
localized disease when symptoms are not controlled by optimized medical treat-
ment. Other indications in literature include recurrent refractory or massive hemop-
tysis, bronchiectasis distal to tumors, and treatment of subsequent complications.
HRCT is the gold standard imaging tool of bronchiectasis, as has a great help in 
preoperative localization of the lesions which affects the decision making for sur-
gery. Preoperative bronchoscopy is important to diagnose the underlying causes of 
bronchial obstruction and to clear the airways by removal of secretions. Preoperative 
PFTs can be performed to determine the segments with little ventilatory contribution 
and minimal effects on postoperative pulmonary function after surgical resection. 
Perfusion scans can be used to determine the most affected non-perfused areas to be 
resected, particularly when the pulmonary function is affected. According to hemo-
dynamic analysis of perfusion scans in diffuse bronchiectasis, surgery can be reserved 
for non-perfused cystic lesions which are more damaged than cylindrical lesions.
Preoperative preparation for lung resection should include sputum culture analysis 
to modify antibiotic therapy with culture sensitivity results. It is crucial to eradicate 
active pulmonary infection and provide prophylactic antibiotic therapy with cephalo-
sporin and aminoglycoside before surgery. Preoperative airway clearance techniques 
including active breathing, oscillating PEP, and postural drainage, are recommended 
to control infection and optimize the respiratory status. Other important preoperative 
considerations include nutritional support and pulmonary rehabilitation.
Posterolateral thoracotomy is the standard approach for the surgical resection 
of bronchiectasis. The extent of resection depends on extent of the disease and 
cardiopulmonary reserve. Preservation of peribronchial tissues, short bronchial 
stump, and buttressing techniques are recommended to reduce postoperative air 
leak and BPF. The safety and feasibility of VATS in the treatment of bronchiectasis 
was shown in scant studies with low morbidity and mortality. The proper care after 
surgery should include bronchoscopic removal of secretions, pain control, chest 
physiotherapy, and appropriate antibiotic therapy.
In literature, the mortality rates after lung resection range from 0.41% to 8.3%. 
The most common causes of early mortality are respiratory failure, intraoperative 
bleeding, postoperative pneumonia, empyema, pulmonary edema, and cardiac-
related causes; while the most common causes of late mortality are respiratory 
failure, progressive respiratory disease, sepsis, coronary artery thrombosis, and cor 
pulmonale. The morbidity rates range from 7–38%. Atelctasis or sputum retention 
is the most common postoperative complication, followed by persistent air leak, 
pneumonia, and BPF. Most of the reported complications are minor, transient, and 
treatable. During follow-up periods between 9 months and 14 years, the proportion 
of asymptomatic patients (excellent improvement) after surgery ranges from 22.3% 
to 89.5%. Postoperative QOL is poorly addressed, but it can be improved after resec-
17
Surgical Management of Bronchiectasis
DOI: http://dx.doi.org/10.5772/intechopen.93103
Author details
Yasser Ali Kamal
Department of Cardiothoracic Surgery, Faculty of Medicine, Minia University, 
El-Minya, Egypt
*Address all correspondence to: yaser_ali_kamal@yahoo.com
Complete resection of the affected parenchyma results in better clinical out-
come than incomplete resection; however, completeness of resection is affected by 
localization of the disease and pulmonary function. A large number of predictors of 
surgical outcomes were investigated in literature, including: type of resection, type 
of bronchiectasis, immuno compromised status, Pseudomonas aeruginosa infection, 
extent of residual bronchiectasis, lack of preoperative bronchoscopic examina-
tion, FEV1 < 60% of the predicted value, tuberculosis, hemoptysis, duration of 
symptoms, age, sputum volume, gram-negative bacillus infection, bronchial stump 
coverage, and impaired pulmonary function.
Recent studies reported acceptable outcomes after a limited lung resection 
for the most predominant lesion in properly selected patients with non-localized 
bronchiectasis. Surgery can be safely performed in children with bronchiectasis, 
particularly when the disease is resectable disease after failure of the proper medical 
treatment. Acceptable postoperative rates of mortality and morbidity and a signifi-
cant symptomatic improvement were reported in children.
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